Glucose transporter inhibitors
Thiazolidinedione compounds and pharmaceutically acceptable salts thereof are described. The compounds can be used in methods of treating cancer in a subject by administering to the subject a therapeutically effective amount of the compound. The compounds can also be used in methods of inhibiting glucose uptake in a cell by contacting the cell with the compound.
1. A compound according to formula I:
wherein R 1 -R 5 are selected from the group consisting of hydrogen, C 1 -C 4 alkyl, halogen, hydroxyl, nitro, amine, C 1 -C 4 alkoxy, and trifluoromethyl;
R 6 is selected from the group consisting of hydrogen, halogen, and C 1 -C 4 alkyl;
and R 7 and R 8 are trifluoromethyl;
and pharmaceutically acceptable salts thereof.
2. The compound according to claim 1 , wherein R 1 and R 5 are hydrogen.
3. The compound according to claim 1 , wherein R 1 , R 4 , and R 5 are hydrogen.
4. The compound according to claim 1 , wherein R 2 is trifluoromethyl and R 3 is hydroxyl.
5. The compound according to claim 1 , wherein the compound has the structure
6. A method of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound according to Formula I:
wherein R 1 -R 5 are selected from the group consisting of hydrogen, C 1 -C 4 alkyl, halogen, hydroxyl, nitro, amine, alkoxy, C 1 -C 4 alkoxy, and trifluoromethyl;
R 6 is selected from the group consisting of hydrogen, halogen, and C 1 -C 4 alkyl;
and R 7 and R 8 are trifluoromethyl;
and pharmaceutically acceptable salts thereof, wherein the cancer is selected from the group consisting of prostate cancer, breast cancer, and pancreatic cancer.
7. The method of claim 6 , wherein R 1 , R 4 , R 5 , and R 6 are hydrogen.
8. The method of claim 6 , wherein R 2 is trifluoromethyl and R 3 is hydroxyl.
9. The method of claim 6 , wherein the compound has the structure
10. The method of claim 6 , wherein the subject is a human.
11. The method of claim 6 , wherein the compound is administered in a pharmaceutically acceptable carrier.
12. A method of inhibiting glucose uptake in a cell by contacting the cell with a compound of formula I:
wherein R 1 -R 5 are selected from the group consisting of hydrogen, C 1 -C 4 alkyl, halogen, hydroxyl, nitro, amine, alkoxy, C 1 -C 4 alkoxy, and trifluoromethyl;
R 6 is selected from the group consisting of hydrogen, halogen, and C 1 -C 4 alkyl;
and R 7 and R 8 are trifluoromethyl;
and pharmaceutically acceptable salts thereof.
13. The method of claim 12 , wherein the compound inhibits GLUT1-mediated glucose uptake.
14. The method of claim 12 , wherein the cell is in vivo.
15. The method of claim 12 , wherein the cell is in vitro.